国际肿瘤学杂志
國際腫瘤學雜誌
국제종류학잡지
JOURNAL OF INTERNATIONAL ONCOLOGY
2015年
6期
426-429
,共4页
杨世荣%赵成茂%王嵘%穆元忠%赵刚
楊世榮%趙成茂%王嶸%穆元忠%趙剛
양세영%조성무%왕영%목원충%조강
胃肿瘤%药物疗法%奥沙利铂%多西他赛%替吉奥
胃腫瘤%藥物療法%奧沙利鉑%多西他賽%替吉奧
위종류%약물요법%오사리박%다서타새%체길오
Stomach neoplasms%Drug therapy%Oxaliplatin%Docetaxel%S-1
目的:比较奥沙利铂联合多西他赛或替吉奥治疗进展期胃癌(AGC)的疗效及安全性。方法选取2011年4月—2013年1月在青海省第五人民医院住院的 AGC 患者共62例,采用随机数字表法将患者随机分为两组,A 组31例接受奥沙利铂联合替吉奥方案,B 组31例接受奥沙利铂联合多西他赛方案;比较两组反应率(RR)、疾病控制率(DCR)、疾病无进展时间、总生存时间和不良反应。结果A 组 RR、DCR、中位疾病无进展时间(mPFS)、中位生存时间(mOS)分别为48.4%、67.7%、5.4个月、9.0个月;B 组相应为54.8%、77.4%、6.2个月、9.8个月,差异均无统计学意义(χ2=0.26,P =0.711;χ2=0.73,P =0.393;χ2=0.51,P =0.473;χ2=0.03,P =0.829)。A 组Ⅰ~Ⅱ级外周神经毒性(9.7%∶22.6%)及恶心呕吐发生率(12.9%∶32.3%)均低于 B 组(χ2=5.78,P =0.002;χ2=4.63,P =0.016)。结论两种化疗方案治疗 AGC 的疗效相当,奥沙利铂联合替吉奥方案可作为进展期胃癌的一种化疗方案,且在耐受性方面优于奥沙利铂联合多西他赛方案。
目的:比較奧沙利鉑聯閤多西他賽或替吉奧治療進展期胃癌(AGC)的療效及安全性。方法選取2011年4月—2013年1月在青海省第五人民醫院住院的 AGC 患者共62例,採用隨機數字錶法將患者隨機分為兩組,A 組31例接受奧沙利鉑聯閤替吉奧方案,B 組31例接受奧沙利鉑聯閤多西他賽方案;比較兩組反應率(RR)、疾病控製率(DCR)、疾病無進展時間、總生存時間和不良反應。結果A 組 RR、DCR、中位疾病無進展時間(mPFS)、中位生存時間(mOS)分彆為48.4%、67.7%、5.4箇月、9.0箇月;B 組相應為54.8%、77.4%、6.2箇月、9.8箇月,差異均無統計學意義(χ2=0.26,P =0.711;χ2=0.73,P =0.393;χ2=0.51,P =0.473;χ2=0.03,P =0.829)。A 組Ⅰ~Ⅱ級外週神經毒性(9.7%∶22.6%)及噁心嘔吐髮生率(12.9%∶32.3%)均低于 B 組(χ2=5.78,P =0.002;χ2=4.63,P =0.016)。結論兩種化療方案治療 AGC 的療效相噹,奧沙利鉑聯閤替吉奧方案可作為進展期胃癌的一種化療方案,且在耐受性方麵優于奧沙利鉑聯閤多西他賽方案。
목적:비교오사리박연합다서타새혹체길오치료진전기위암(AGC)적료효급안전성。방법선취2011년4월—2013년1월재청해성제오인민의원주원적 AGC 환자공62례,채용수궤수자표법장환자수궤분위량조,A 조31례접수오사리박연합체길오방안,B 조31례접수오사리박연합다서타새방안;비교량조반응솔(RR)、질병공제솔(DCR)、질병무진전시간、총생존시간화불량반응。결과A 조 RR、DCR、중위질병무진전시간(mPFS)、중위생존시간(mOS)분별위48.4%、67.7%、5.4개월、9.0개월;B 조상응위54.8%、77.4%、6.2개월、9.8개월,차이균무통계학의의(χ2=0.26,P =0.711;χ2=0.73,P =0.393;χ2=0.51,P =0.473;χ2=0.03,P =0.829)。A 조Ⅰ~Ⅱ급외주신경독성(9.7%∶22.6%)급악심구토발생솔(12.9%∶32.3%)균저우 B 조(χ2=5.78,P =0.002;χ2=4.63,P =0.016)。결론량충화료방안치료 AGC 적료효상당,오사리박연합체길오방안가작위진전기위암적일충화료방안,차재내수성방면우우오사리박연합다서타새방안。
Objective To evaluate the efficacy and safety of combination therapy of oxaliplatin and S-1 vs oxaliplatin and docetaxel for advanced gastric cancer (AGC)patients.Methods From April 201 1 to Janu-ary 201 3,62 cases of AGC were collected in the Fifth People′s Hospital of Qinghai Province.All cases were randomly divided into group A (31 cases)and B (31 cases)by random number table.In group A,oxaliplatin plus S-1 was administered,and in group B,oxaliplatin plus docetaxel was applied.The response rate (RR), time of diseases controlled rate (DCR),progression-free survival (PFS),overall survival (OS)and adverse reactions of the two groups were observed and compared.Results There were no statistically differences between group A and group B in RR (48.4% vs 54.8%),DCR (67.7% vs 77.4%),mPFS (5.4 months vs 6.2 months),mOS (9.0 months vs 9.8 months),and the statistical values were as follows:χ2 =0.26,P =0.71 1 ;χ2 =0.73,P =0.393;χ2 =0.51 ,P =0.473;χ2 =0.03,P =0.829.The incidence of degrees Ⅰ-Ⅱperipheral neuropathy (9.7% vs 22.6%),nausea and vomiting (1 2.9% vs 32.3%)in group A were signifi-cantly lower than those in group B (χ2 =5.78,P =0.002;χ2 =4.63,P =0.01 6).Conclusion Both the two chemotherapies are similar in therapeutic effect for patients with AGC.Oxaliplatin plus S-1 treatment may be better than oxaliplatin plus docetaxel in the tolerance of patients.